Schering-Plough Sued in NJ for Marketing Drugs for Off-Label Uses

A raft of lawsuits centered in New Jersey allege that Schering-Plough offered bribes and other incentives to doctors to get them to prescribe its hepatitis and cancer drugs for uses not approved by the FDA. Five of six lawsuits filed are pending in New Jersey federal court. But plaintiffs in the sixth suit, filed in Arizona, are asking for that matter to be centralized in Arizona or Massachusetts, where a federal off-label marketing probe ended with Schering agreeing to pay a $180 million criminal fine.

This article requires premium access

This article requires premium access to Law.com. Please sign in or subscribe to read the full text.